(P03-064-24) Effectiveness of a Patient-Specific Oligoantigenic Diet on Global Symptoms for Irritable Bowel Syndrome

Objectives: To investigate the effectiveness of a 12-week patient-specific oligoantigenic diet on global symptomatology for irritable bowel syndrome (IBS).

Methods: Preliminary data from a prospective single-arm study (NCT05178017) of 28 adults with IBS were analyzed. Blood specimens were collected to conduct the in-vitro leukocyte activation assay-MRT (LAA-MRT^TM) using a flow cytometry system. The Lifestyle Eating and Performance (LEAP) program is a patient-specific oligoantigenic diet built using the LAA-MRT^TM results. The LEAP program was administered virtually in phases by eliminating moderate- to high-immune-reactive foods and chemicals by a registered dietitian nutritionist (RDN). A Global Symptom Survey (GSS) was utilized to evaluate the severity and frequency of symptoms associated with IBS. The GSS contains 13 domains, rated on a scale of 0 – 4, with a minimum score of 0 and a maximum of 308 points. A higher score indicates more frequent and severe symptoms. An independent Institutional Review Board (IRB) approved the study.

Results: Subjects’ age was 50.0±17.0 years, BMI 26.3± 6.8 kg/m², and 25 (89.3%) were female. After following the dietary treatment for 12 weeks, there were significant improvements for ten domain scores: a) Constitutional: 10.4±6.4 vs. 4.6±5.1, t(27)=4.8, p< 0.001, 95% CI (3.3, 8.3), d=0.9; b) Emotional/ Mental: 9.4±7.2 vs. 4.5±5.3, t(27)=3.8, p< 0.001, 95% CI (2.2, 7.4), d=0.7; c) Head/Ears: 4.3±4.6 vs. 2.9±4.5, t(27)=2.3, p=0.027, 95% CI (0.2, 2.6), d=0.4; d) Skin: 3.2±3.0 vs. 1.4±1.5, t(27)=3.5, p=0.002, 95% CI (0.8, 2.8), d=0.7; e) Nasal/ Sinus: 5.6±5.7 vs. 2.9±4.5, t(27)=2.9, p=0.007, 95% CI (0.8, 4.7), d=0.5; f) Mouth/Throat: 2.2±3.5 vs. 0.6±1.1, t(27)=2.4, p=0.021, 95% CI (0.3, 3.0), d=0.5; g) Musculoskeletal: 7.1±5.4 vs. 3.0±4.2, t(27)=4.7, p< 0.001, 95% CI (2.3, 5.8), d=0.9; h) Cardiovascular: 0.6±1.0 vs. 0.3±0.7, t(27)=2.2, p=0.036, 95% CI (0.02, 0.6), d=0.4 ; i) Digestive: 18.4±7.9 vs. 5.0±4.8, t(27)=8.9, p< 0.001, 95% CI (10.3, 16.5), d=1.7; j) Weight Management: 4.4±4.0 vs. 1.6±3.5, t(27)=4.2, p< 0.001, 95% CI (1.4, 4.1), d=0.8.

Conclusions: Subjects with IBS reduced global symptom scores following a patient-specific oligoantigenic diet. The LAA-MRT^TM identifies adverse reactions to foods and additives, allowing for personalized dietary modifications.

Funding Sources: Oxford Biomedical Technologies, Inc.